PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) priced a private offering of $500 million 0% Convertible Senior Notes due 2031, with an option for an additional $50 million. The notes carry no cash interest, mature June 15, 2031, and are senior unsecured.
According to PTC Therapeutics, net proceeds of about $486.8 million will primarily refinance its 1.5% Convertible Senior Notes due 2026, including a concurrent cash repurchase of $222 million principal for a total cost of approximately $328.8 million. The initial conversion price is $107.48, a 40% premium to the June 15, 2026 close.
Positive
- Raises approximately $486.8 million in net proceeds from 0% convertible notes
- Refinances $222 million principal of 1.5% 2026 notes via cash repurchase
- Eliminates regular cash interest on new $500 million 2031 notes
- Extends debt maturity profile out to June 15, 2031
- Initial conversion price set at $107.48, a 40% premium to $76.77 share price
Negative
- Total repurchase cost of 2026 notes is $328.8 million for $222 million principal
- Convertible structure introduces potential equity dilution at $107.48 conversion price
- Additional senior unsecured debt of up to $550 million including option
News Market Reaction – PTCT
In the Jun 16 session, PTCT declined 4.56%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.6% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.7x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings results | Positive | +14.3% | Q1 2026 beat with raised full‑year revenue guidance and strong cash balance. |
| May 04 | Investor conferences | Neutral | +0.5% | Announcement of participation in multiple upcoming healthcare investor conferences. |
| Apr 28 | Clinical trial data | Positive | -8.1% | Positive 24‑month PIVOT‑HD extension results for votoplam in Huntington’s disease. |
| Apr 28 | Clinical update call | Neutral | +1.5% | Scheduled webcast to discuss PIVOT‑HD long‑term extension data and next steps. |
| Apr 22 | Earnings date set | Neutral | +0.8% | Announcement of date and time for Q1 2026 financial results and business update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent major fundamental updates (earnings, key clinical readout) have produced sizable price swings, while scheduling-type announcements had modest, generally positive moves. Positive clinical data once coincided with a negative reaction.
Over the past several months, PTC Therapeutics has mixed financial and clinical catalysts. On May 7, 2026, strong Q1 2026 results and raised revenue guidance drove a 14.27% gain. Positive 24‑month PIVOT‑HD extension data on April 28, 2026 saw an 8.13% decline despite encouraging efficacy, showing that good clinical news does not always translate into upside. Conference participation and earnings‑date notices in late April and early May produced small, positive moves, indicating investors respond more strongly to concrete results than scheduling updates.
Key Terms
convertible senior notes financial
private placement financial
rule 144a regulatory
sinking fund financial
fundamental change financial
indenture financial
nasdaq global select market financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –
– Offering made at
The Notes will be general senior unsecured obligations of PTC, and will not bear regular interest and the principal amount of the Notes will not accrete. The Notes will mature on June 15, 2031, unless earlier converted, repurchased or redeemed.
PTC estimates that the net proceeds from the Offering will be approximately
PTC expects to use approximately
Prior to the close of business on the business day immediately preceding March 15, 2031, holders will have the right to convert their Notes only upon the satisfaction of specified conditions and during certain periods. On or after March 15, 2031 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time. Upon conversion, PTC will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election.
The conversion rate for the Notes will initially be 9.3042 shares of PTC's common stock per
PTC may not redeem the Notes prior to June 20, 2029. On or after June 20, 2029, PTC may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of PTC's common stock has been at least
If PTC undergoes a "fundamental change" (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, holders may require PTC to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to
Concurrently with the pricing of the Notes in the Offering, PTC entered into private negotiated transactions with certain holders of the 2026 Notes to repurchase for a total repurchase cost (including accrued and unpaid interest) of approximately
In connection with any repurchase of the 2026 Notes, PTC expects that holders of the 2026 Notes who agreed to have their 2026 Notes repurchased may enter into or unwind various derivatives with respect to PTC's common stock and/or purchase shares of PTC's common stock concurrently with or shortly after the pricing of the 2026 Notes. In particular, PTC expects that certain holders of the 2026 Notes employ a convertible arbitrage strategy with respect to the 2026 Notes and have a short position with respect to PTC's common stock that they will close out through purchases of PTC's common stock and/or the unwinding of various derivatives with respect to PTC's common stock, as the case may be, in connection with PTC's repurchase of the 2026 Notes. This activity could increase (or reduce the size of any decrease in) the market price of PTC's common stock, which may also affect the trading price of the Notes at that time. This activity may have affected the market price of PTC's common stock prior to, concurrently with or shortly after the pricing of the Notes, and could result in a higher effective conversion price of the Notes. PTC cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or PTC's common stock.
The Notes were only offered by means of a private offering memorandum. The offer and sale of the Notes and any shares of PTC's common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any shares of PTC's common stock issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.
For more information please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
Cautionary Note Regarding Forward-Looking Statements:
The press release contains information about future expectations, plans and prospects of PTC's management that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements with respect to PTC's expectations to complete the Offering of the Notes, its use of proceeds from the Offering and the effect of the concurrent note repurchase. There can be no assurance that PTC will be able to complete the notes offering on the anticipated terms, or at all. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, the terms of the Notes and the Offering, risks and uncertainties related to whether or not PTC will consummate the Offering, the impact of general economic, industry, market or political conditions and other factors that are discussed in PTC's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents periodically filed with the Securities and Exchange Commission.
In addition, the statements in this press release represent PTC's expectations and beliefs as of the date of this press release. PTC anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while PTC may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's expectations or beliefs as of any date subsequent to the date of this press release.
View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-pricing-of-convertible-notes-offering-to-refinance-2026-convertible-notes-302801013.html
SOURCE PTC Therapeutics, Inc.